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Abstract
Triphenyltin coumarin-3-carboxylate and its coordination complexes with ethanol, triphenylphosphine oxide,
triphenylarsine oxide, diphenylcyclopropenone and quinoline N-oxide exhibited high in vitro cytotoxicity
(LCso values in the range 0.25-3.4 lag/mL) when tested against EBV-DNA positive Raji cells and P-388
leukaemia cells, compared to the standard drug 5-Fluorouracil, which showed LCs0 values of 11 and >50
tag/mL, respectively, against these cells. Additional tests performed on the Raji cells incubated with the
quinoline N-oxide complex in the presence of the tumour promoters, TPA and sodium butyrate, revealed that
the diffused and restricted protein components of the early antigen complex were suppressed relative to the
control containing only the promoters, indicating impaired function of the genes involved as transactivators
in the early lyric cycle of the EBV. The failure of the restriction enzymes Eco R1 and Hind III to cleave the
extracted DNA from such treated cells in contrast to the control, coupled with the amplification of the
BMLF-I gene by the PCR technique which was realised only with the DNA of the control and not of the
treated sample, point to a punitive interaction ofthe organotin with the nuclear DNA ofthe Raji cells.
Introduction
A large number of di-and tri-organotin compounds exhibit in vitro anti-tumour properties against a wide
variety of human tumour cell lines’, including Ehrlich ascites tumour, IMC carcinoma, P-388 lymphocytic
leukaemia, Sarcoma 180, MCF-7 and EVSA-T (mammary tumours), WiDr (a colon cancer), IGROV (an
ovarian canoe0, A 498 (a renal canoe0, M 9 MEL (a melanoma) and H 226 (a lung cancer). However, there
is no previous study on nasopharyngeal carcinoma (NPC) involving organotins. This disease has much
epidemiological significance in Southeast Asia and the Far East on account of the genetic predisposition of
the malignancy among the Chinese populationT.
Malignant neoplasms in the nasopharynx is a heterogeneous group of tumours, among which are
certain types which are associated with the Epstein Barr virus (EBV)s’9, a B lymphotropic human herpes
virus which is transmitted primarily in saliva or, less commonly, by blood transfusion. The virus is often
found in the latent state in many human cell lines, but can be induced into the lytic cycle by a variety of
agents, including superinfection with the P3HR-1 strain of EBV, phorbol ester (12,O-tetradecanoylphorbol
-13-acetate [TPA]) or sodium butyrate. The mechanism of the induction by TPA is not well understood, but
there is evidence that the induction is at the transcriptional level. A number of genes in the EBV genome,
among them BZLF-I, BMLF-1, BMRF-I and BRLF-1 have been identified as transactivators in the early
lytic cycle’ Of these, the BZLF-1 and BMLF-1 genes are considered to play major control roles in the
switch from the latent to the lytic viral cycle. The BMLF-1 gene, which encodes one of the early antigen
(EA) proteins that is expressed in the lytic state, has been shown to have a promoter region and two well
defined activation sites upstream to the transcription start site that are inducible by the phorbol ester .
In this study, we have investigated the in vitro cytotoxic effects of triphenyltin coumarin 3-carboxylate
and its coordination complexes with monodentate oxygen donor ligands against the EBV-DNA positive Raji
and the P-388 murine leukaemia cancer cell lines. The common chemotherapeutic drug, 5-Fluorouracil, was
included in the screening tests. [Triphenyltin coumarin -3-carboxylate oQuinoline-N -oxide], which proved
to be the most active against the Raji cells, was selected for a detailed investigation of its effect on the
expression of the EBV-EA complex in the lytic cycle of the virus induced by the combined use13 of TPA and
sodium n-butyrate. Using anti-EA polyclonal antibodies derived from patients with NPC as probes, we have
demonstrated that the organotin suppressed both the diffused and restricted components
14 of the EA complex.
In the context of the inhibition of TPA induction, we have also examined the integrity of the DNA isolated
from the treated Raji cells relative to the control, including that of the PCR-amplified BMLF-I gene fragment
in both situations. Our observations here are included in this paper.
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Materials and Methods
Materials
Triphenyltin coumarin-3-carboxylate and its 1"1 or 2:1 monomeric complexes obtained when the
Lewis acid is mixed with equimolar amounts of various monodentate oxygen donor ligands were synthesised
as previously reported5. TPA, sodium n-butyrate and 5-Fluorouracil were Sigma products. The NPC cell
line used was the EBV-DNA positive Raji cell line obtained from NCI (Bethesda); the P-388 cell line was
procured from American Type Culture Collection. The cells were routinely maintained as per standard
protocol in RPMI 1640 and Dulbecco minimum essential medium, respectively, with each medium
supplemented with 10% fetal calfserum and antibiotics.
CytotoxiciF assay
Cells growing in the logarithmic phase were used in the assay. Each well of a 96- well microtitre
plate was charged with 300 L of the cell suspension containing approximately 2x105 cells. The cells, with
the exception of the control, were incubated with 3 laL of the test solutions in the concentration range 500
ng/mL to 10 lag/mL made up in DMSO. The plate was placed in a humidified incubator (37 C; 5% CO2 ) for
24-48 h. A 1:1 ratio of cell suspension to Tryphan Blue (0.1% solution in phosphate buffered saline [PBS]
was then prepared in a separate microtitre plate, and a drop of this was placed on a haemocytometer for
viewing and cell count using an inverted microscope (20x objective). Only dead cells took up the blue stain.
Plots of percentage inhibition (based on the ratio, Number of cells alive /Total cell count) against the
concentrations of the test compound used yielded LCs0 (concentration at which the test compounds caused
one-half of the cells to be killed) values. An average of 2-3 readings for each concentration of the test
compound was used for the cytotoxicity evaluation.
IndirectImmunofluorescence Assay
Raji cells in the logarithmic phase and at a density of 2x10 cells/mL were incubated with the
organotin test compound at various concentrations between the IDa0 value and 10 lag/mL in the presence of
the promoters 20 ng/mL TPA and 4 mM/mL sodium butyrate. The control contained only the promoters. The
cells were incubated for 72 h in a humidified incubator (37 C; 5% CO2) before being harvested. A drop of
the cell suspension (in 100 laL PBS) was placed into each well of a multitest Teflon-coated slide and fixed
with acetone. 20 laL of EBV-EA positive serum obtained from patients suffering from nasopharyngeal
carcinoma (polyclonal antibodies), previously diluted 20 fold in PBS, was dispensed into each well and the
bound antibody detected using a second antibody against the first, in this case, goat anti-human IgG,
previously labelled with fluorescein- isothiocyanate. The fluorescent Raji cells embodying antigen-antibody
interactions were observed under an UV microscope; their number decreased markedly when higher
concentrations oforganotin were used in the treatment.
Detection ofEarly Antigen protein suppression by the Western Blot technique
Control and organotin-treated Raji cells were washed with PBS at 4 C and, in the presence of an
equal volume of the detergent sodium dodecyl sulphate (SDS), heated at 100 C for 10 min. After cooling,
the chromosomal DNA was sheared by sonication. The sample was then centrifuged at 10,000g for 10 min.
and the supernatant containing the cellular protein collected. Approximately 100 lag of the protein was
loaded onto a 0.75 mm thick 12% SDS polyacrylamide gel and electrophoresis performed on it using 100 V.
Prestained SDS-PAGE standards of low molecular weight were used as protein markers. The separated
protein bands on the gel were then transferred (blotted) on to a 0.2 thick Immobilon polyvinylidene
difluoride (PVDF) membrane electrophoretically by sandwiching the gel and the membrane, which had
previously been soaked in a transfer buffer, between two electrodes. Transfer was achieved in approximately
h using 21 V. The membrane was removed and soaked for 1-2 h in a blocking solution of non-fat milk in
PBS to block any subsequent, non-specific adsorption of antibodies by the membrane. The membrane was
then incubated overnight with NPC serum previously diluted 200 fold using the blocking solution. Excess
antibodies were then washed from the membrane and the bound antibody which remained was detected using
a second antibody, namely affinity- purified goat anti-human IgG horseradish peroxidase conjugate (BIO-
RAD), diluted in phosphate-free blocking solution. Following incubation for h, the membrane was soaked
for 10 min in a solution of 150 mM NaCl and 50 mM Tris-HCl and then immersed in the HRP colour
development solution. After the bands appeared, the membrane was air dried and photographed.
DNA extraction and analysis
Control and organotin-treated Raji cells were washed with PBS and centrifuged as described in the
previous section. The supernatant was discarded and the residue was treated with 500 L of the lysis buffer.
Standard laboratory procedures
t6 were followed in removing protein and RNA by sequential incubations with
proteinase K and ribonuclease A, and in extracting the DNA finally into ethanol. The extracted DNA was
analysed by electrophoresis using 0.8% agarose gel. The location of the DNA bands within the gel was
facilitated by including 0.5 g/mL of the fluorescent dye ethidium bromide in the gel. kb DNA ladder and
Hind III markers were used as reference.
Digestion ofPlasmidpBR322 with (a) organotin and (b) Hind III
PBR 322 bacterial plasmid was incubated with the restriction enzyme Hind III digest as well as
separately with various concentrations of [triphenyltin coumarin-3-acetate oQuinoline N-oxide] in Eppendorf
tubes at 37 C for 2 h in a water bath. At the end of the incubation period, the samples were subjected to
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electrophoresis using 1.4% agarose gel containing a small amount of ethidium bromide, and the fluorescent
DNA bands observed underUV light.
Digestion ofRajiDNA with Eco RIandHindIII restriction enzymes
Extracted DNA (6.0 tL) from Raji cells, both organotin-treated and control, were incubated with
Eco R1 and Hind III (each 3.0 laL) in separate experiments in the presence of the standard restriction
enzyme digestion mixture, and at a temperature of 37 C for 2 h. The samples were then subjected to
electrophoresis as described above.
Amplification ofthe BMLF-I gene by Polymerase Chain Reaction (PCR)
Template DNA (5.0 laL) from control and organotin-treated Raji cells was mixed with EBV BMLF-
primer set, deoxynucleotide triphosphate and Taq DNA polymerase (reagents obtained from Maxim
Biotech, Inc.), and the PCR carried out for 35 cycles as per standard protocol7. Each cycle ofPCR consisted
of thermal denaturation at 94 C, primer annealing at 55 C and extension at 72 C, all carried out in the
automated thermal cycler (Perkin- Elmer Cetus). The amplified samples were then purified just once
employing the PURE-GENE PCR purification kit and then subjected to electrophoresis on 1.5% agarose gel
containing 0.5 lag/mL ethidium bromide. DNA ladders of 100 bp as well as kbp were used as markers to
detect the characteristic 265 bp band ofthe BMLF-1 gene.
Results and Discussion
Cytotoxicity assay
The LCs0 values of the organotin compounds screened against the Raji and P-388 cell lines are
shown in Table 1. The data clearly show that against both cancer cell lines the organotins (all pentacoordinate
at tin) were significantly more cytotoxic than the standard drug, 5-Fluorouracil. The organotins appeared to
be all uniformly active against the Raji cells, with the quinoline- N-oxide complex, [TPTCCoQuinO],
Table 1. Cytotoxicity data for triphenyltin coumarin-3-carboxylate and its coordination complexes
with monodentate ligands against the Raji and P-388 cell lines in comparison with 5-Fluorouracil
Compounds
Triphenyitin c0umarin-3-
Raji cells
(LCso g/mL)
1.05
carboxylate (TPTCC)
[TPTCC][TPTCC Ph3PO]
[TPTCC EtOH]
[TPTCC][TPTCC PhaAsO]
[TPTCC DPCP]
[TPTCC- QuinO]
5-Fluorouracil
1.0
1.2
0.65
1.0
0.45
>50
P-388celis
(LCso Iag/mL)
3.4
0.75
2.1
0.25
0.35
1.75
11.0
registering marginally greater activity than the others. This compound, therefore, was chosen for further
experiments with the Raji cells. Against the P-388 cell line, the organotin complexes were more active than
the parent organotin carboxylate Lewis acid, with the complexes containing the ligands triphenylarsine oxide
and diphenyl cyclopropenone (DPCP) exhibiting greater activities. Whereas a concentration of lag/mL of
5-Fluorouracil was required to obtain 50% inhibition of growth of the P-388 cells, approximately the same
concentration of [TPTCCoQuinO] caused 100% inhibition.
Inhibition ofEBV-Early Antigen proteins by organotin
Incubation of the EBV genome-positive Raji cells in the logarithmic growth phase with TPA and
sodium n-butyrate caused the induction of the lytic viral cycle with expression of the early antigen complex
(EA). This was evidenced by the successful binding of the EA to the added polyclonal antibodies introduced
from the EBV-EA positive serum obtained from patients suffering from nasopharyngeal carcinoma, as
detected by the indirect immunofluorescence assay. Relative to the control (Fig.l, left), the number of
fluorescent Raji cells embodying antigen-antibody interactions decreased in the organotin-treated case, with
the inhibitory effect being more pronounced when higher organotin concentrations were used in the
treatment. Concentrations of 50,100,200 and 400 ng/mL of the organotin, [TPTCCoQuinO], were used in the
study; total suppression of the EBV-EA was achieved at the 200 ng/mL concentration level (Fig.l, right).
With the triphenylarsine oxide complex, completely non-fluorescent cells were obtained only at the treatment
concentration of600 ng/mL.
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Fig. 1: Immunofluorescence staining patterns in (left) untreated Raji cells (control)
showing induction ofEBV-EA by TPA and sodium n-butyrate and (right) Raji cells treated
with [TPTCCoQuinO] at 200 ng/mi concentration showing absence ofEBV-EA induction.
The Westem Blot technique was next used to investigate whether the organotin affected either or
both the restricted and diffused protein components of the early antigen complex. Previous studies using
monoclonal antibodies have conclusively demonstrated4’s that the 85 kDa protein is a distinguishing
characteristic of EA(R), a methanol-sensitive antigen restricted to the cytoplasm, while two major protein
bands in molecular weight range 47-56 kDa are associated with EA(D), a methanol resistant and largely
intranuclear antigen. Fig. 2 depicts the Western Blot in which lanes 6-9 relate to protein bands obtained from
Raji cells treated with [TPTCCoQuinO]. The suppression of both EA(R) and EA(D) is evident at the higher
organotin concentrations of200 and 400 ng/mL.
Conceivably, the concentration-dependent inhibitory effect of the organotin could arise as a result of
the blockage of the TPA-and-sodium butyrate promotion of the genes that function as transactivators in the
early lytic cycle of the virus. As pointed out in the Introduction, one of these is the BMLF-1 gene. This
implies interaction of the organotin with the nuclear DNA and hence with the resident EBV genome to
varying levels during incubation. To test this point, we examined the integrity of the DNA extracted from the
organotin-treated Raji cells relative to the control.
Studies on theDNA ofRail cells
Upon electrophoresis using 0.8% agarose gel, a difference in the DNA pattem between the control and
organotin-treated samples was observed: the DNA band ofthe control sample was located at around 23 kbp,
1 2 3456 7 89
Fig. 2: Western Blot depict of the suppression of EBV-EA(R) (85 kDa) and EA(D) (47-56 kDa) by
[TPTCCQuinOi
Loading sequence: Lanes: (1) empty;(2) prestained marker-low range molecular weight proteins;(3) Control
(un.treated) Raji cells;(4) & (5) Control+TPA+sodium butyrate;(6) Raji cells+TPA+sodium
butyrate+organotin 50 ng/mL (7) Raji cells+TPA+sodium butyrate+organotin 100 ng/mL (8) Raji
cells+TPA+sodium butyrate+organotin 200ng/mL (9) Raji cells +TPA + sodium butyrate +organotin 400
ng/mL.
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while for the case of the treated sample an immobile band, perhaps obstructed by the pore size of the gel, was
seen at a higher molecular weight (Fig. 3). While this is not necessarily indicative of a chemical interaction
between the organotin and the DNA, to enable a better appraisal of this possibility we subjected the extracted
DNA to cleavage by restriction enzymes. The restriction enzymes, Hind III and Eco R1, which are known to
Fig. 3: Agarose gel electrophoregram of extracted DNA from untreated (control) and organotin-
treated Raji cells
Loading sequence: Lanes: (1) empty; (2) kb DNA ladder; (3) & (4) DNA from control sample; (5) empty;
(6) & (7) DNA from organotin-treated sample; (8) HIND III marker (0.12-23.1 kb)
have different specific recognition sites on DNA, were used for this purpose. In the case of the control
sample, electrophoregram of the DNA excised by Hind III digestion showed a smear of several
indistinguishable bands (10 kb and below) but only a single band at around 10 kb was noticed for the treated
sample (Fig. 4, left). This suggests an inability of the restriction enzyme to cleave the apparently modified
DNA in the latter case. A similar result (Fig. 4, right) was also obtained for the case ofthe Eco R1 cleavage.
Fig. 4: Agarose gel electrophoregrams of extracted DNA from control (incubation only
with TPA- sodium butyrate) and treated (incubation with TPA-sodium butyrate and organotin) Raji
cell samples following digestion with HIND III (left) and Eco Rl (right)
Loading sequence: Lanes: (1) empty; (2) kb DNA ladder; (3) control sample undigested with restriction
enzyme; (4) control sample digested with restriction enzyme; (5) treated sample undigested with restriction
enzyme (6) treated sample digested with restriction enzyme (7) Z. HIND II1 marker
To rule out the possibility that the organotin might have itselfpartially fragmented the DNA and yielded a
low molecular weight fraction that perhaps had escaped detection on agarose gel, a test was performed using
a different DNA substrate, namely, the circular plasmid pBR322. This is a 4363 bp vector with unique
recognition sites for Hind III cleavage in its Tc (tetracycline resistant) gene. Incubation ofthe plasmid DNA
with this restriction enzyme yielded a single band upon analysis by agarose gel electrophoresis, in contrast
to two configurationally discernible DNA bands which were observed for each ofthe untreated plasmid and
the organotin- incubated plasmid.
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In the context ofthe above observations, it was of interest to determine whether the BMLF- gene
specific to the EBV-EA protein had been rendered ineffective as a result ofthe treatment ofthe Raji cells
with the organotin. Applying the polymerase chain reaction, this target gene was amplified in the control and
Fig. 5: Agarose gel electrophoresis analysis of the PCR product from the amplification of the BMLF-I
gene performed on DNA extracted from organotin-treated and untreated (control) Raji cells
Loading sequence: Lanes: (1) empty; (2) 100 bp DNA ladder; (3-6) control sample (previously incubated
only with TPA-sodium butyrate); (7) treated sample (previously incubated with TPA-sodium butyrate and
organotin (OT)) (1 lag/mL OT); (8) treated sample (2 lag/mL OT); (9) treated sample ((3 tag/mL OT).
treated Raji samples using the primer set having the sequences shown below:
50ligo: 5’ CTT GGA GAC AGG CTT AAC CAG ACT CA 3’
3 Oligo: 5’ CCA TGG CTG CAC CGA TGA AAG TTA T 3’
The amplified samples were then subjected to electrophoresis in 1.5% agarose gel. As depicted in Fig. 5, the
treated samples drew a blank in the electrophoregram relative to the control which yielded the characteristic
265 bp band of the BMLF-I gene, suggesting that the organotin had affected the expression of this viral gene
as a result of its punitive interaction with the Raji cell DNA. Although the evidence for the interaction of the
organotin with DNA is only indirect, the result interestingly is at variance with previously reported
observations of the selective accumulation of organotins in the Golgi apparatus and endoplasmic reticulum
region of cells rather than in the nucleus4.
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